Loading
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations is a phase 1/2 interventional study registered as NCT06644768 by Daiichi Sankyo, with 137 participants planned, started 2024-10-30 and due to reach its primary completion in 2028-03-30. Interventions recorded: valemetostat tosylate, pembrolizumab. Conditions listed: Non-small Cell Lung Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Daiichi Sankyo, Small-cell lung cancer, Pembrolizumab.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.